This trial studies a new drug to see if it's safe & effective against advanced solid tumors.
- Solid Tumors, Adult
4 Primary · 7 Secondary · Reporting Duration: Up to 2.5 years
4 Treatment Groups
1 of 4
1 of 4
1 of 4
1 of 4
35 Total Participants · 4 Treatment Groups
Primary Treatment: Cohort 2 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 11 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is there availability for participants to join this research project?
"The search for eligible participants is currently ongoing, as evidenced by the December 6th 2022 posting and subsequent edit found on clinicaltrials.gov." - Anonymous Online Contributor
Are there any research centers in North America that are actively conducting this clinical trial?
"This exploration into the efficacy of a new treatment is currently being conducted at 5 centres, including those in Los Angeles, Detroit and Morristown. Prospective participants should select the closest site to minimize their travelling obligations." - Anonymous Online Contributor
Have the results of Cohort 1 been validated by the FDA?
"Cohort 1's safety score is a conservative 1 due to the minimal data that exists on its efficacy and general security." - Anonymous Online Contributor
How many individuals are participating in this clinical experiment?
"Affirmative. The information on clinicaltrials.gov portrays that this medical trial is actively recruiting patients, with the original post being published December 6th 2022 and edited most recently on the same day. 35 persons will be recruited from 5 different sites for participation in this study." - Anonymous Online Contributor
What are the chief aims of this clinical experiment?
"This clinical trial, spanning a duration of up to 3 years, seeks to identify the Recommended Phase 2 Dose (RP2D) of Decoy20. Also being assessed are secondary outcomes such as Area under the concentration versus time curve (AUC), anti-drug antibodies (ADA) and maximum drug concentration (Cmax). These pharmacokinetic parameters will be determined pre-dose and post-dose on Day 28 after administering Decoy20." - Anonymous Online Contributor